Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development
Aurealis Therapeutics AG
ID Pharma Co Ltd
RemeGen Co Ltd
Ribomic Inc
Zucero Therapeutics Ltd
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile
Product Description
Mechanism Of Action
Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
pixatimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBM-007 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RC-28 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TR-764 - Drug Profile
Product Description
Mechanism Of Action
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones
Featured News & Press Releases
Apr 19, 2022: RIBOMIC announces completion of IND submission for an observatiol study for continuous phase 2 trial of RBM-007 for treatment of Achondroplasia
Mar 23, 2022: RIBOMIC provides update on RBM-007 program in wet age-related macular degeneration
Dec 28, 2021: RIBOMIC announces prelimiry topline data from phase 2 trials of RBM-007 for wet age-related macular degeneration
Nov 15, 2021: RIBOMIC announces RBM-007 phase 1 clinical trial results for achondroplasia
Sep 30, 2021: RIBOMIC announces presentation of masked prelimiry interim data from phase 2 trials of RBM-007 for wet age-related macular degeneration at the Reti Society 2021 Meeting
Aug 30, 2021: RIBOMIC completes patient enrollment of its US phase 2 open-label extension clinical trial of RBM-007 for wet age-related macular degeneration (RAMEN Study)
Aug 05, 2021: RIBOMIC completes patient enrollment of its US phase 2 clinical trial of RBM-007 for wet age-related macular degeneration (TOFU Study)
Jul 12, 2021: RIBOMIC announces first patient dosed in an investigator sponsored trial of RBM007 in treatment ?ve wet AMD patients
May 12, 2021: RIBOMIC announces completion of its phase I trial of RBM-007 for the treatment of achondroplasia
May 06, 2021: RIBOMIC announces publication of research paper on aptamer drug discovery for achondroplasia
Feb 01, 2021: Ribomic announces completion of 50% of enrollment of its phase 2 clinical trial for wet age-related macular degeneration (TOFU study)
Nov 11, 2020: RIBOMIC announces initiation of RAMEN open-label extension clinical trial for RBM007 in wet AMD patients
Jul 15, 2020: RIBOMIC announces dosing of first subject in RBM-007 phase 1 clinical trial for Achondroplasia
May 11, 2020: Safe-to-proceed under IND to initiate clinical trials of RBM-007 for treatment of achondroplasia
May 07, 2020: RIBOMIC resumes trial recruitment suspended by corovirus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aurealis Therapeutics AG, 2022
Pipeline by ID Pharma Co Ltd, 2022
Pipeline by RemeGen Co Ltd, 2022
Pipeline by Ribomic Inc, 2022
Pipeline by Zucero Therapeutics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022